INTRODUCTION AND OBJECTIVES: MIBC patients who respond to cisplatin based NAC, defined as stage <ypT2 at cystectomy, exhibit a high 5 year cancer specific survival (CSS) of up to 90%. In contrast, non-responders (stage ¼ypT2 at cystectomy) exhibit a worse CSS (30-40%) than cystectomy alone, highlighting the need for predictors of NAC response. Recent MIBC studies have identified a gene expression based taxonomy (basal versus luminal phenotypes) similar to that of breast cancer. We evaluated the role of such a classification using immunohistochemical stains in a NAC cohort of MIBC.
INTRODUCTION AND OBJECTIVES: MIBC patients who respond to cisplatin based NAC, defined as stage <ypT2 at cystectomy, exhibit a high 5 year cancer specific survival (CSS) of up to 90%. In contrast, non-responders (stage ¼ypT2 at cystectomy) exhibit a worse CSS (30-40%) than cystectomy alone, highlighting the need for predictors of NAC response. Recent MIBC studies have identified a gene expression based taxonomy (basal versus luminal phenotypes) similar to that of breast cancer. We evaluated the role of such a classification using immunohistochemical stains in a NAC cohort of MIBC.
METHODS: Pre-treatment tissues from a cohort of 71 NAC treated MIBC patients at our institution between 2000 and 2013 were incorporated in tissue microarray and stained for CK5/6 and GATA3 (Ventana Medical Systems, AZ). Cases were assigned as luminal or basal phenotype based on the extent (70% cut off) of tumor cells with ¼2+ staining intensity, Figure 1A . We limited our analysis of CSS to the 40 patient who were able to tolerate ¼2 doses of NAC to avoid the confounding effect of patients who were not adequately dosed.
RESULTS: As expected, there was an inverse association for CK5/6 and GATA3: 77% (43/56) of strong GATA3 cases exhibited weak/negative CK5/6 staining, most consistent with the luminal phenotype, and 73% (11/15) of the GATA3 weak/negative cases exhibited strong CK5/6, most consistent with the basal phenotype (Fisher's exact p-value 0.0003). Interestingly there was a~2 fold enrichment of basal the phenotype in cases with residual MIBC following NAC, Figure 1B .
CONCLUSIONS: Our results suggest a differential responsiveness to NAC for MIBC based on assignment of basal and luminal phenotypes. The current findings should be further evaluated taking P53 gene expression status into account, given previous suggestion of chemotherapy resistance in P53 intact (p53-Like) MIBC. Furthermore, comparison to IHC luminal/basal MIBC phenotypes in our cohort of cystectomy only treated patients is ongoing to help discern the prognostic vs predictive role of this classification for NAC. 
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INTRODUCTION AND OBJECTIVES:
It has been reported that lymph node density is superior to TNM nodal status in predicting oncologic outcome after radical cystectomy (RC) for urothelial carcinoma of bladder (UCB). The survival benefits of adjuvant chemotherapy (AC) following RC according to LND were assessed in this study.
METHODS: Of 888 consecutive UCB patients undergoing RC with pelvic lymph node dissection (PLND), 164 (18.5%) received the AC. After controlling preoperative and postoperative clinical and pathological variables, recurrence-free (RFS) and cancer-specific survival (RFS) after RC with PLND were compared between the AC and non AC groups.
RESULTS: After the strict propensity scored matching (both discard, caliper¼0.1), 130 patients with AC were not significantly different with 130 matched patients without AC, in age (62.5 vs. 61.8 years), pT stage (pT3, 78.5 vs. 77.7%), pN stage (pN1, 23.8 vs. 30.8% ;pN2, 32.3 vs. 32.3%), tumor grade (high, 95.4 vs. 87.7%), carcinoma in situ (23.1 vs. 28.5%), lymphovascular invasion (62.3 vs. 58.5%), positive surgical margin (10.0 vs. 10.0%), dissected LN number (19.8 vs. 22.4) , and LN density (0.14 vs. 0.15; p range, 0.071-1.000). During median 43.0 months follow-up after the RC with PLND, median RFS of AC group was similar to that of non AC group (37.0 vs. 30.0 months, p¼0.612). CSS were not also different between two groups (60.0 vs. 55.0 months, p¼0.313). However, better RFS (20.0 vs. 9.0 months, p¼0.008) and CSS (44.0 vs. 18.0 months, p¼0.009) of AC group were observed in subgroup of patients with LND 0.05 (N¼122). CONCLUSIONS: After adjusting the possible confounders and selection biases, AC demonstrated better oncological outcomes in patients with LND 0.05. Patients with LND 0.05 on final pathology should be considered the AC for better survival outcomes. 197, No. 4S, Supplement, Sunday, May 14, 2017 
